Literature DB >> 3757407

Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects.

A G Mallinger, D J Edwards, J M Himmelhoch, S Knopf, J Ehler.   

Abstract

We investigated the pharmacokinetics of tranylcypromine, as well as the relationship between plasma levels of this agent and its effects on blood pressure and pulse rate. Tranylcypromine was absorbed rapidly after oral dosing, with the peak level being attained within 0.67 to 3.50 hours. Absorption was biphasic in seven of nine subjects. Elimination of tranylcypromine also was rapid, with a t 1/2 between 1.54 and 3.15 hours. From 2 to 7 hours after dosing, standing systolic and diastolic blood pressures were lowered and standing pulse was raised, compared with baseline. Onset of the effect on standing systolic blood pressure was correlated with the time of peak plasma tranylcypromine concentration. Maximum orthostatic drop of blood pressure and rise of pulse rate occurred 2 hours after dosing. Mean plasma tranylcypromine concentrations were correlated with mean orthostatic drop of systolic blood pressure and rise of pulse rate. Patients who have clinically significant hypotensive reactions to this agent may benefit from changes in their dose regimen aimed at minimizing peak tranylcypromine levels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757407     DOI: 10.1038/clpt.1986.205

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Neurochemical and metabolic aspects of antidepressants: an overview.

Authors:  G B Baker; R T Coutts; A J Greenshaw
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 2.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

3.  Liquid chromatographic estimation of tranylcypromine in human plasma.

Authors:  P G Krugers Dagneaux; C P Loohuis; J T Klein Elhorst; T S Van der Veer
Journal:  Pharm Weekbl Sci       Date:  1992-04-24

Review 4.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 5.  Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature.

Authors:  Connor J Kinslow; Steven D Shapiro; Michael F Grunebaum; Eliza C Miller
Journal:  J Neurol Sci       Date:  2018-07-31       Impact factor: 3.181

Review 6.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.

Authors:  Natalia Mast; Mark Andrew White; Ingemar Bjorkhem; Eric F Johnson; C David Stout; Irina A Pikuleva
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-09       Impact factor: 11.205

8.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

Review 9.  Metabolism of monoamine oxidase inhibitors.

Authors:  G B Baker; L J Urichuk; K F McKenna; S H Kennedy
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

10.  Neurochemical and neuropharmacological properties of 4-fluorotranylcypromine.

Authors:  R T Coutts; T S Rao; G B Baker; R G Micetich; T W Hall
Journal:  Cell Mol Neurobiol       Date:  1987-09       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.